Danaher Forecasts High-End of Prior Guidance, Citing Bioprocessing Strength
By Nicholas G. Miller
Danaher forecasted fourth-quarter revenue growth and full-year earnings to both come in toward the high end of the company's prior guidance on the back of strength in bioprocessing.
The company said it expects adjusted core revenue growth for the fourth quarter to be toward the high end of its prior guidance of low-single digit percentage growth.
It also said that for the full fiscal 2025, it anticipates adjusted earnings to come in toward the high end of its previous forecast of $7.70 to $7.80 a share.
"We were especially pleased with continued strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in the fourth quarter," said Chief Executive Rainer Blair.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
January 12, 2026 09:35 ET (14:35 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
